10-Q: NeuroPace Q2 2026: Revenue Up, But Losses Persist

NeuroPace reported a 17% increase in revenue for Q2 2026, reaching $22.8 million, but continued to post net losses and saw a decrease in cash and cash equivalents.

Summary

• NeuroPace reported revenue of $22.8 million for the three months ended June 30, 2026, a 17% increase from $19.5 million in the same period of 2025.
• For the six months ended June 30, 2026, revenue was $44.8 million, up 19% from $37.8 million in the prior year period.
• The company experienced a net loss of $6.2 million for the three months ended June 30, 2026, compared to a net loss of $8.7 million in the prior year period.
• For the six months ended June 30, 2026, the net loss was $12.9 million, an improvement from $15.2 million in the prior year period.
• Cash, cash equivalents, and short-term investments decreased to $51.7 million as of June 30, 2026, from $61.1 million at December 31, 2025.
• The company received a notification from the FDA stating that its PMA-S for drug-resistant idiopathic generalized epilepsy is not approvable in its current form, requesting additional information.
• The DIXI Medical product operations have been classified as discontinued operations, with no revenue generated from this segment in the three months ended June 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to continued net losses and a decrease in cash reserves, despite revenue growth. The FDA's non-approvable letter for the PMA-S is a significant concern.

Positives

• Revenue increased by 17% to $22.8 million for the three months ended June 30, 2026, compared to $19.5 million in the prior year period.
• Revenue increased by 19% to $44.8 million for the six months ended June 30, 2026, compared to $37.8 million in the prior year period.
• Gross margin remained strong at 82.8% for the three months and 82.4% for the six months ended June 30, 2026.
• General and administrative expenses decreased by 17% for the three months and 2% for the six months ended June 30, 2026, partly due to a reduction in severance costs.
• The company remains in compliance with all covenants of the MidCap Credit Agreement as of June 30, 2026.
• The company's RNS System demonstrated a 62.5% median seizure reduction at six months and 82.0% at 36 months in its post-approval study.

Negatives

• The company incurred a net loss of $6.2 million for the three months ended June 30, 2026, and $12.9 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and short-term investments decreased to $51.7 million as of June 30, 2026, from $61.1 million at December 31, 2025.
• The FDA has indicated that the PMA-S for drug-resistant idiopathic generalized epilepsy is not approvable in its current form, requiring further information and communication.
• The company's gross margin slightly decreased from 83.1% to 82.8% for the three-month period and from 82.9% to 82.4% for the six-month period, due to slightly higher material costs.
• Sales and marketing expenses increased by 6% for the three months and 8% for the six months, driven by increased personnel costs.
• Net income from discontinued operations was $1.4 million in Q2 2025, but zero in Q2 2026 due to the cessation of DIXI Medical product sales.

Risks

• Failure to successfully market and sell the RNS System cost-effectively and maintain/expand market share could negatively affect sales and operations.
• The company depends on a limited number of single-source suppliers, making it vulnerable to supply shortages and price fluctuations.
• Inability to accurately forecast customer demand could harm results of operations.
• The company may be unable to compete successfully with other treatment options for focal epilepsy.
• Failure to obtain adequate reimbursement for procedures and ongoing care could diminish sales or profitability.
• The FDA's notification that the PMA-S is not approvable in its current form poses a significant risk to the expansion of indications.
• The company has a history of net losses and expects to continue incurring losses for the foreseeable future.

Future Outlook

The company expects to continue incurring net losses and negative cash flows in the near term due to ongoing investments in research and development and commercial activities. Management believes current cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next 12 months. However, the company may require additional funding.

Management Comments

• We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment.
• As disclosed on July 28, 2026, the Company received correspondence from the FDA notifying it that the PMA-S is not approvable in its current form and requesting additional information and further interactive communication.
• We intend to continue making significant investments in research and development, clinical studies and regulatory affairs to support ongoing and future regulatory submissions for retaining and expanding indications of our RNS System.

Industry Context

StockSavvy.ai notes that NeuroPace operates in the competitive medical device market for epilepsy treatment. The company's RNS System is a novel brain-responsive neuromodulation device. The key challenge remains market acceptance and expanding indications, particularly with the recent FDA feedback on their PMA-S filing.

Comparison to Industry Standards

• NeuroPace's gross margin of approximately 82% is generally considered strong for a medical device company, often exceeding industry averages which can range from 50-70% depending on the sub-sector.
• The company's net loss per share of $0.18 for the quarter is a common characteristic for early-stage medical device companies investing heavily in R&D and commercialization, though sustained losses are a concern.
• Competitors like LivaNova and Medtronic in the neuromodulation space have longer operating histories and greater resources, setting a high bar for market penetration and adoption.

Legal Proceedings

• The company is not currently involved in any material legal proceedings.

Related Party Transactions

• In February 2025, the company used $49.5 million of proceeds from a follow-on offering to repurchase shares from its significant stockholder, KCK Ltd.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• The FDA's decision on the PMA-S could negatively impact future growth prospects and investor confidence.
• Clinicians and patients may be impacted by the company's efforts to expand the RNS System's indications and market reach.

Next Steps

• Submit a Submission Issue Request to the FDA to discuss the PMA-S approach.
• Amend the PMA-S with supplemental information, including additional data and context regarding patient populations from the NAUTILUS trial.
• Continue investing in research and development, clinical studies, and regulatory affairs for RNS System indications.
• Expand sales and marketing efforts to drive awareness and increase patient referrals.

Key Dates

Recommendation

While revenue growth is positive, the continued net losses, decreasing cash reserves, and the significant setback with the FDA's non-approvable letter for the PMA-S introduce considerable risk. The company's ability to achieve profitability and expand its market hinges on overcoming these challenges. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the FDA submission and the company's path to profitability.

Keywords

epilepsy, neuromodulation, RNS System, drug-resistant epilepsy, focal epilepsy, seizure reduction, FDA, PMA-S